塔尔苏斯制药

关于 Tarsus Pharmaceuticals

Tarsus 制药, Inc. is a commercial stage biopharmaceutical company 专注于 the 开发 and commercialization of therapeutics, starting with eye care. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being 开发 for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was 成立 by Bobak Azamian and D. Michael Ackermann in 2017 and is 总部位于 in Irvine, CA.

成立时间

2017

首席执行官

Dr. Bobak Azamian, M.D.,PhD

员工人数

370

总部地址

Irvine, California, United States of America

财年结束日

12-31

官方网站

tarsusrx.com

公司概况

交易所

US

股票代码

TARS

市值排名

#2389

上市日期

2020-10-16

市值

3.19B

流通市值

2.43B

总股数

46.79M

流通股数

35.65M

行业与主题板块

浏览全部行业与主题板块